Breast Oncology

Annals of Surgical Oncology

, Volume 20, Issue 11, pp 3469-3476

Breast-Conserving Therapy Achieves Locoregional Outcomes Comparable to Mastectomy in Women with T1-2N0 Triple-Negative Breast Cancer

  • Zachary S. ZumstegAffiliated withDepartment of Radiation Oncology, Memorial Sloan-Kettering Cancer Center
  • , Monica MorrowAffiliated withDepartment of Surgery, Memorial Sloan-Kettering Cancer Center
  • , Brittany ArnoldAffiliated withDepartment of Radiation Oncology, Memorial Sloan-Kettering Cancer Center
  • , Junting ZhengAffiliated withDepartment of Epidemiology-Biostatistics, Memorial Sloan-Kettering Cancer Center
  • , Zhigang ZhangAffiliated withDepartment of Epidemiology-Biostatistics, Memorial Sloan-Kettering Cancer Center
  • , Mark RobsonAffiliated withDepartment of Medicine, Memorial Sloan-Kettering Cancer Center
  • , Tiffany TrainaAffiliated withDepartment of Medicine, Memorial Sloan-Kettering Cancer Center
  • , Beryl McCormickAffiliated withDepartment of Radiation Oncology, Memorial Sloan-Kettering Cancer Center
  • , Simon PowellAffiliated withDepartment of Radiation Oncology, Memorial Sloan-Kettering Cancer Center
    • , Alice Y. HoAffiliated withDepartment of Radiation Oncology, Memorial Sloan-Kettering Cancer Center Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Background

Conflicting data exist regarding optimum local therapy for early-stage triple-negative breast cancer (TNBC). We examined outcomes according to local treatment type in a large cohort of node-negative TNBC patients.

Methods

A total of 1,242 consecutive patients with TNBC treated at a single institution from 1999 to 2008 were identified. Of these, 646 with pathologic stage T1-2N0 TNBC underwent breast-conserving therapy (BCT) (N = 448) or total mastectomy (TM) without postmastectomy radiation (N = 198) and comprised the study population. Locoregional recurrence (LRR), distant metastasis (DM), and overall recurrence were investigated with a competing risk analysis using Gray’s test and multivariable Fine and Gray competing risk regression. Overall survival was assessed using standard Kaplan–Meier methods and a Cox proportional hazards analysis.

Results

Median follow-up was 78.3 months (range 1–156). Eight-one percent of patients received adjuvant chemotherapy. TM patients were younger, were more likely to have lymphovascular invasion, and had larger tumors than patients undergoing BCT (all P ≤ 0.05). The 5-year cumulative incidence of LRR was 4.2 and 5.4 % for patients undergoing BCT and TM, respectively. There was no significant difference in LRR, DM, overall recurrence, disease free survival, or overall survival between groups on univariate analysis, or after adjusting for other variables in multivariate models. Lack of chemotherapy and high tumor stage independently predicted for decreased overall survival (both P < 0.001).

Conclusions

A low, 5-year risk of LRR (4.7 %) was achieved in a large group of women with T1-2N0 TNBC treated with multimodality therapy. BCT was as equally effective as TM for local and distant control.